Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma.

ABSTRACT: With the introduction of immune checkpoint inhibitors (ICIs) and next-generation vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs), the survival of patients with advanced renal cell carcinoma (RCC) has improved remarkably. However, not all patients have benefited from treatments, and to date, there are still no validated biomarkers that can be included in the therapeutic algorithm. Thus, the identification of predictive biomarkers is necessary to increase the number of responsive patients and to understand the underlying immunity. The clinical outcome of RCC patients is, in fact, associated with immune response. In this exploratory pilot study, we assessed the immune effect of TKI therapy in order to evaluate the immune status of metastatic renal cell carc

SUBMITTER: Zizzari IG 

PROVIDER: S-EPMC7563741 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature